logo-loader

4D Pharma PLC about to start dosing patients in its Phase II trial for COVID-19

Published: 10:01 29 May 2020 EDT

4D pharma plc's (LON:DDDD) Duncan Peyton tells Proactive London's Andrew Scott they're focused on live biotherapeutics - a new class of therapeutics which uses bacteria as drugs.

''Even though it's a new area we've made a lot of progress in the five years we've been going ... we've got our own manufacturing and a really strong IP position and we've just finished some more clinical trials so it's really going well''.

4D has active clinical programmes in areas including oncology and asthma as well as COVID-19 in which they're due to start a Phase II trial shortly.

Poseidon Nickel signs binding agreement with Mineral Resources to divest...

Departing Poseidon Nickel Ltd (ASX:POS, OTC:PSDNF) CEO Craig Jones and incoming CEO Brendan Shalders join Proactive’s Jonathan Jackson to discuss the divestment of Lake Johnston to Mineral Resources Ltd (ASX:MIN). Jones, who has played a pivotal role in this strategic move, shared insights on...

1 hour, 31 minutes ago